Global GEO vs Local AI Search in Pharma: Why Global Content Doesn’t Guarantee Local AI Citations

Does a global Generative Engine Optimization (GEO) program help a pharma brand get cited correctly when a patient in Mumbai or a physician in Rio de Janeiro asks an AI chatbot about a specific drug? The honest answer is: partly. Global GEO builds the raw material AI systems draw from, but language, local regulatory bodies, patient vocabulary, and country-specific source ecosystems still decide what actually surfaces in a local answer.

Two layers of GEO that get conflated

Most pharma teams run one “GEO strategy” and assume it covers every market. In practice it is useful to separate two layers:

• Global GEO — the content assets built once and meant to be authoritative everywhere: mechanism-of-action pages, clinical trial data hubs, structured glossaries, schema markup, pipeline pages. These are engineered to be machine-readable and citation-worthy regardless of who is asking.
• Local GEO — everything shaped by the market itself: the approved indication wording, reimbursement status, the local guideline bodies a query pulls in (HAS or ANSM in France, NICE or the MHRA in the UK, the FDA in the US), the brand name actually used locally, and the language of the query.

The confusion between the two is where most “why aren’t we showing up in [country]” conversations start. Sounds familiar?

How generative engines actually localize an answer

Retrieval-augmented generative engines (ChatGPT with browsing, Perplexity, Google AI Overviews, Copilot) don’t apply one global index uniformly. Query language changes what gets retrieved and how the answer is generated. A 2024 study on cross-language retrieval-augmented generation (preprint, not yet peer-reviewed) found that large language models display a systemic bias toward retrieving and answering from sources written in the same language as the query, and that when no source exists in the query’s language, models default to pulling from whichever language has the most available content — typically English — reinforcing the dominant view rather than reflecting local nuance¹.

A more recent study measured this directly on brand-level content: researchers queried three grounded models (GPT, Gemini, and Perplexity) about 66 European brands in twelve languages and found that AI-constructed reputation is, in their words, “language-bound” — answers generated in the same language family were measurably more similar to each other than answers generated across language families for the same underlying entity.² A companion analysis of the citations behind 128 brands across 12 markets found that the source mix itself shifts by market: in Poland, for example, the most-cited domain for many national brands was YouTube rather than Wikipedia, and local HR and careers portals out-cited the local Wikipedia edition roughly two to one.

These two studies were run on general consumer brands, not pharmaceutical products specifically, and the exact figures should not be read as pharma benchmarks. But the underlying mechanism they document — that query language and market change which sources get pulled into an AI-generated answer about the same entity — applies to any topic a generative engine retrieves for, health included.

Why this matters more in pharma than in most categories

For most product categories, a language-driven shift in cited sources is a visibility problem. In pharma, it can also be a substantive accuracy problem, because the underlying facts genuinely differ by country — this is not an artifact of AI, it predates it.

Regulators do not always agree on how a drug should be described. A widely cited comparison of oncology approvals reviewed by both the EMA and the FDA between 1995 and 2008 found that of 100 shared indications, 19 were approved by only one of the two agencies, and 28 carried differently worded labels, 10 of which the authors judged clinically meaningful — for example, one kinase inhibitor was approved as a second-line kidney-cancer treatment in the EU but as a first-line treatment in the US.⁴ A separate comparison of FDA and EMA decisions found that roughly half of shared drug approvals carried identical label wording, while about 20% were approved by one agency and not the other, and 28% differed in indication wording⁵ — broadly consistent with the first study’s figures. A 2013–2023 comparison of the two agencies’ approval patterns attributes part of this divergence to differing regulatory philosophies: the FDA has historically taken a more exploratory approach to approval, while the EMA leans more public-health-oriented in its risk-benefit assessment.⁶

An AI system that answers a query about a drug’s approved use with unified confidence — without flagging that the approved indication, line of therapy, or label wording differs by country — inherits, and can amplify, a discrepancy that already existed in the regulatory record. That is a different and higher-stakes problem than a brand simply being under-cited in a given market.

Local authority signals still decide who gets trusted

Google’s Search Quality Rater Guidelines classify health content as “Your Money or Your Life” (YMYL), the category subject to the strictest scrutiny for accuracy and source trustworthiness; the September 2025 revision added, for the first time, explicit criteria for how raters should evaluate AI Overview responses on these topics.⁷ The practical implication for pharma is that the local equivalents of the FDA and PubMed — bodies such as ANSM, HAS, and Vidal in France, the MHRA and NICE in the UK, or IQWiG in Germany — function as the trusted reference points a careful person would be expected to consult in that market. A global content hub, however well structured, does not automatically inherit the authority these local bodies carry for a French- or German-language query; being referenced by them, or matching their terminology, is a distinct and separate signal.

Experience and lay-language alignment: a second reason local content wins for patients

Two more signals point the same direction, and they are strong enough to state a clear position on: yes, both push weight toward local content over global content — more so for patient-facing pages than for HCP-facing ones.

Experience. Google added “Experience” to E-A-T in December 2022, explicitly to capture content produced by someone with first-hand, life experience with a topic, alongside formal expertise.⁸ In pharma, formal expertise — mechanism of action, trial data, regulatory science — is inherently global; it does not change by country. Patient experience, by contrast, is inherently local: what a French patient experiences on a treatment pathway is shaped by the French reimbursement and prescribing system and French-language patient communities, not by a country-agnostic global asset.

EU regulators formally recognize this same category of evidence: a review of EMA-approved non-oncology medicines from 2018–2022 found that patient-reported outcome statements are increasingly included directly in the official Summary of Product Characteristics and package leaflet — the documents used to inform prescribers and patients.⁹ If both Google and EU regulators treat patient experience as a distinct, locally grounded category of evidence, a single global content asset cannot structurally carry it — only market-specific content built with local patient voice can.

Semantic and vocabulary alignment. Patients search the way patients talk, not the way clinical documents are written, and the gap is well documented: consumers habitually use everyday terms (“high cholesterol,” “heart attack”) rather than the clinical terms (“hyperlipidemia,” “myocardial infarction”) used in professional and regulatory content — a divergence significant enough that researchers built a dedicated Consumer Health Vocabulary specifically to bridge it, now integrated into the U.S. National Library of Medicine’s Unified Medical Language System.¹⁰ The EU has built the equivalent requirement directly into pharmaceutical regulation: since 1998, and reinforced in 2009, package leaflets in the EU must undergo formal readability and comprehension testing with at least 20 patients drawn from the population the medicine is intended for, precisely because clinical language does not reliably communicate to lay readers.¹¹ This vocabulary gap does not translate cleanly across languages — the everyday term a French patient uses is not simply a dictionary translation of the term an English-speaking patient would use — so content optimized around one market’s patient vocabulary will not automatically match how patients phrase the same concern elsewhere.

This matters for generative engines specifically, not just classical SEO, because retrieval works by matching the semantic content of a query to the semantic content of a source. The Princeton GEO study tested this directly: simplifying language — its “Easy-to-Understand” tactic — measurably improved a page’s visibility in generative-engine answers, by roughly 10–30% depending on the engine, trailing only citation- and statistics-based tactics.¹² A globally written, clinically worded page is, by construction, further from how a given market’s patients actually phrase their question — a second and independent reason, beyond source-language bias, that global content under-performs locally for patient queries.

So yes, both Experience and semantic/vocabulary alignment appear to push weight toward local content, and more so for patient-facing pages than HCP-facing ones, where formal expertise and clinical precision remain the dominant signal. This is a reasoned inference from combining GEO, E-E-A-T, and pharma-regulatory evidence.

Where global GEO does transfer across markets

None of this means global GEO work is wasted — it means it operates on a different layer than local visibility. The foundational academic study on this discipline, published by researchers from Princeton, Georgia Tech, the Allen Institute for AI, and IIT Delhi, tested nine content-optimization tactics across 10,000 queries and found that techniques such as adding statistics, citing sources, and including relevant quotations could improve a page’s visibility in generative-engine answers by up to 40% on average — while also showing that the size of the effect varies significantly by domain, arguing for domain-specific rather than one-size-fits-all optimization.¹²

Applied to pharma, this suggests two things travel well across markets regardless of query language:

• Structural citability — schema markup, clearly sourced statistics, and well-organized mechanism-of-action and trial-data pages raise the baseline probability that a domain gets retrieved and quoted at all, in any language, because these are largely language- and market-agnostic signals of a “citable” page.
• Entity consistency — consistent naming and structured data across language versions of a site help generative engines resolve a company and its French, German, or Polish name variants as the same underlying entity, which is a prerequisite for any of that global authority to transfer locally in the first place.

Where it breaks down for pharma specifically

Three gaps are pharma-specific and won’t be closed by global content alone:

• Off-label exposure — content written around one market’s approved indications, if surfaced without geographic framing in a market where that indication is not authorized, creates a distinct compliance risk on top of the ordinary citation-accuracy risk every category faces.
• Similar concerns apply to OTC/Rx status.
• Reimbursement and access — whether a treatment is publicly reimbursed, and under what conditions, is a national decision (by bodies such as HAS in France or NICE in the UK) that a global content asset cannot represent correctly for every market simultaneously.
• Naming and molecule identity — INN (international non-proprietary name) versus local brand name, and the arrival of biosimilars or generics under different market names, changes what a local-language query even resolves to before source retrieval starts.

A practical starting audit

1. Run the same set of representative queries in three to five languages across ChatGPT (with browsing), Perplexity, and Google AI Overviews; record which sources are cited for each language/market pair.
2. For each market, note whether local regulatory or health-authority sources (ANSM, HAS, MHRA, NICE, national medicines agencies) appear in the citation mix, or whether the answer leans on English-language/global sources by default.
3. Classify existing content into what should remain a single global asset (mechanism of action, pipeline, global trial-registry data) versus what needs a genuine local variant (approved indication wording, reimbursement status, safety labeling).
4. Repeat the audit on a recurring basis — model versions, retrieval behavior, and the underlying source ecosystem change often enough that a one-time check goes stale quickly.
5. For patient-facing content specifically, check whether the wording matches how local patients actually phrase the concern (lay vocabulary, not a translated clinical page) and whether it carries a locally grounded patient-experience signal — not just a reused global expertise claim.

The takeaway

A global GEO initiative is necessary groundwork — it is what makes a pharma brand citable at all. But it is not sufficient to guarantee accurate, locally grounded visibility, because generative engines retrieve and weigh sources differently depending on the language of the query and the local authority ecosystem, because patient-facing content is judged partly on locally grounded experience and vocabulary that a translated global page cannot supply, and because pharma regulatory facts genuinely diverge by country in ways a single global answer cannot represent. Treating global and local GEO as two coordinated layers — rather than one program — is what closes that gap.

This article is an editorial analysis for marketing and content strategy purposes. It is not legal, regulatory, or medical advice; pharma organizations should confirm compliance requirements with qualified regulatory and legal counsel in each market before acting on any of the practices discussed.

References

1. Sharma, N., Murray, K., & Xiao, Z. (2024). Faux Polyglot: A Study on Information Disparity in Multilingual Large Language Models. arXiv:2407.05502. Preprint, not peer-reviewed. 
2. Žatuchin, D. (2026). The Language Blind Spot: How Query Language and Brand Recognition Tier Shape AI-Constructed Brand Reputation Across Twelve European Languages. arXiv:2606.23165.
3. Žatuchin, D. (2026). How Large Language Models Source Brand Reputation Across Languages and Markets. arXiv:2606.25787.
4. Trotta, F., Tafuri, G., et al. (2011). Comparative data on FDA/EMA oncology label divergence, as reported in “Approval rating: how do the EMA and FDA compare?” Cancer World, archived edition.
5. Howie LJ, Hirsch BR, Abernethy AP. A comparison of FDA and EMA drug approval: implications for drug development and cost of care. Oncology (Williston Park). 2013 Dec;27(12):1195, 1198-1200, 1202 passim.
6. Lau F, Seifert R. Comparison of drug approvals of the FDA and EMA between 2013 and 2023. Naunyn Schmiedebergs Arch Pharmacol. 2026 Jan;399(1):279-299. 
7. Google. Search Quality Rater Guidelines, September 11, 2025 edition.
8. Google Search Central Blog. “Our latest update to the quality rater guidelines: E-A-T gets an extra E for Experience.” December 2022.
9. Sauchelli S, Levy C, Gnanasakthy A, Dave V, Doward L, Fitzgerald KA, Carson R. From clinical trials to informing clinical decision-making: a review of patient-reported outcomes in nononcology medicines approved by the European Medicines Agency (2018-2022). Front Pharmacol. 2025 Apr 11;16:1536401.
10. Zeng QT, Tse T. Exploring and developing consumer health vocabularies. J Am Med Inform Assoc. 2006 Jan-Feb;13(1):24-9.
11. Pires C, Vigário M, Cavaco A. Readability of medicinal package leaflets: a systematic review. Rev Saude Publica. 2015;49:4.
12. Aggarwal, P., Murahari, V., Rajpurohit, T., Kalyan, A., Narasimhan, K., & Deshpande, A. (2024). GEO: Generative Engine Optimization. In KDD 2024 – Proceedings of the 30th ACM SIGKDD Conference on Knowledge Discovery and Data Mining (pp. 5-16). (Proceedings of the ACM SIGKDD International Conference on Knowledge Discovery and Data Mining). Association for Computing Machinery. 

Olivier Gryson, PharmD, MSc
25 years of experience in digital marketing in the pharmaceutical industry
Special focus on AI Search in Pharma Marketing